AUPH News and Press, Aurinia Pharmaceuticals Inc From 01/24/23

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the United States Patent and Trademark Office (USPTO) has allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia’s newly allowed U.S. Patent Appl...

Summary Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD. The latest clinical trials on Ensifentrine u...

Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH) were up by 79.6% this week as of late Friday afternoon, according to data provided by S&P Global Market Intelligence . The biopharmaceutical company, which specializes in treating autoimmune disorders, closed las...

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) has reported prelim net revenue of ~$28.4M for fourth quarter compared to consensus estimate of $27.13M. For the three months ended Dec. 31, 2022, preliminary unaudited net revenues included net product revenues of ~$28.3M and license a...

Preliminary unaudited net revenue for the fourth quarter and full year 2022 of approximately $28.4 million and $134.0 million Preliminary unaudited net product revenue for the fourth quarter and full year 2022 of approximately $28.3 million and $103.5 million Reiterates net produc...

Summary Aurinia Pharmaceuticals Inc. recently settled a patent dispute with Sun Pharma. That seems to have rekindled buyout chatter. However, without an actual buy - which is an unpredictable event - Aurinia Pharmaceuticals has no upside, given poor voclosporin sales. In m...

Summary Aurinia Pharmaceuticals recently announced they have reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Both companies will dismiss their claims and counterclaims against each other. Following the settlement announcement, AUPH shares jump...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that Peter Greenleaf, President and Chief Executive Officer, is scheduled to present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11 th at 4:30 p.m. Pacific Time / 7:30 p.m....

Aurinia Pharmaceuticals ( NASDAQ: AUPH ) rose 5% amid speculation the company may be a takeover target after Tuesday's patent settlement with Sun Pharmaceuticals. Aurinia ( AUPH ) surged 38% on Tuesday after the company said it reached a settlement with India's Sun Pharmac...

Canada-based Aurinia Pharmaceuticals ( NASDAQ: AUPH ) on Tuesday said it had reached a settlement with India's Sun Pharmaceuticals ( OTCPK:SMPQY ) over its patent challenge of its lupus nephritis treatment Lupkynis. AUPH shares were 36.1% higher to $5.88 after the opening bell...